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Neuroprotection after traumatic brain injury (TBI) is an important goal pursued strenuously 
in the last 30 years. The acute cerebral injury triggers a cascade of biochemical events 
that may worsen the integrity, function, and connectivity of the brain cells and decrease 
the chance of functional recovery. A number of molecules acting against this deleterious 
cascade have been tested in the experimental setting, often with preliminary encouraging 
results. Unfortunately, clinical trials using those candidate neuroprotectants molecules 
have consistently produced disappointing results, highlighting the necessity of improving 
the research standards. Despite repeated failures in pharmacological neuroprotection, 
TBI treatment in neurointensive care units has achieved outcome improvement. It is 
likely that intensive treatment has contributed to this progress offering a different kind 
of neuroprotection, based on a careful prevention and limitations of intracranial and 
systemic threats. The natural course of acute brain damage, in fact, is often complicated 
by additional adverse events, like the development of intracranial hypertension, brain 
hypoxia, or hypoperfusion. All these events may lead to additional brain damage and 
worsen outcome. An approach designed for early identification and prompt correction of 
insults may, therefore, limit brain damage and improve results.
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PAneL: KeY POinTS FOR iMPROvinG PReCLiniCAL ReSeARCH
• Evaluation of drug effects in animal models considering different:
⚬ Types and severity of lesion
⚬ Species
⚬ Age, sex, comorbidities
• Assessment of early and late functional and histological outcomes
• Clinically relevant therapeutic window
• Well-elucidated mechanism of action and pharmacokinetics of the candidate compound
• Replication of the effect in different independent laboratories
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inTRODUCTiOn
Progress in neurosurgery, neuroradiology, and critical care medi-
cine in the last 50 years (1) contributed to the drops of 9% per dec-
ade in traumatic brain injury (TBI) mortality among hospitalized 
patients between 1970 and 1990, and it has been stable since (2). 
However, TBI remains a major cause of mortality and morbidity: 
approximately 57,000 deaths related to TBI occur in the European 
Union every year (3). Moreover, the increasing proportion of 
survivors includes many with neurological disabilities and poor 
quality of life (4); it was estimated that 7.7 million patients live 
with TBI-related disabilities in Europe (5). For all these reasons, 
neuroprotective strategies could provide immense benefits.
Even if there is no broadly accepted definition, neuroprotec-
tion in TBI can be considered as the body of interventions aimed 
at improving the patient’s outcome, and preserving and restoring 
the integrity, function, and connectivity of the brain cells not irre-
mediably damaged by the initial injury. While the primary injury 
at the moment of the impact (including hemorrhage, laceration, 
contusion, and primary axotomy) is not amenable to medical 
treatment, the complex cascade of molecular and cellular events 
(secondary injury) that follows the original damage can aggravate 
the initial harm. This cascade reduces the chances of functional 
recovery but could, at least theoretically, be counteracted (6, 7).
The first section of this paper discusses attempts to limit the 
progression of injury, focusing on preclinical research, and trans-
lational medicine. In the second section, we describe therapeutic 
interventions based on multimodal brain monitoring that could 
reduce the extent of additional insults to the injured brain.
neUROPROTeCTiOn in PReCLiniCAL 
ReSeARCH AnD TRAnSLATiOnAL 
MeDiCine
Traumatic brain injury is the result of an external force applied 
to the head (8) which, depending on the energy and site of the 
impact, can result in a number of different lesions commonly 
referred to as primary injury. Contusions, lacerations, epidural 
hematomas, subdural hematomas, subarachnoid hemorrhage, 
and axonal injury may be seen in TBI patients, based on the dif-
ferent mechanisms of the injury (direct impact, acceleration and 
deceleration forces, penetrating object, explosion blast waves), 
singly or in combination.
Beyond the brain tissue disruption at the moment of the impact, 
a broad spectrum of secondary events is triggered by the initial 
biomechanical injury. This include acute, subacute, and chronic 
events that all contribute to cell death and/or degeneration and 
are referred to as secondary brain injury (9). Briefly, alteration 
in ionic permeability and release of excitatory neurotransmitters 
(especially glutamate) propagate damage through energy failure 
and free radicals overload. Spreading depolarization is thought 
to be linked to this excessive release of glutamate. Cellular 
permeability is altered and increases calcium influx; this causes 
mitochondrial dysfunction, priming further energy defects, and 
apoptosis. Neurons ultimately may die through necrotic and 
apoptotic processes; autophagy is believed to play a role as well. 
Damaged axons may further fall prey to secondary axotomy and 
demyelination. Trauma directly affects the blood–brain barrier, 
with increased permeability causing protein-rich edema, and 
activation of a pro-inflammatory state. Inflammation, also pro-
moted by resident microglia, has a dual action, spreading damage 
and, at the same time, promoting neurorestorative processes. This 
complex series of events starts immediately (seconds or min-
utes) after trauma but may last for weeks or months, especially 
inflammation (4). The contributions of each of these pathways 
to the secondary brain injury vary depending on the specific 
TBI lesion; for example, inflammation-mediated brain injury 
seems predominant in contusion while calcium-mediated injury 
predominates in diffuse axonal injury (10).
Several TBI models reproduce specific types of lesion in 
homogeneous groups of animals. Based on the distinct force 
applied, they can be used to investigate the components of the 
primary and secondary injury in time and space. Each model 
has specific advantages and limitations (9). None of them can be 
considered ideal, but together they lead to an understanding of 
mechanisms contributing to cell death or dysfunction after TBI. 
Consequently, experimental models have allowed the identifica-
tion of therapeutic targets and the study of a wide spectrum of 
neuroprotective molecules including drugs aiming at specific 
targets (such as calcium-antagonists, NMDA-antagonists, free 
radical scavengers, bradykinin antagonists) and also drugs target-
ing multiple/pleiotropic mechanisms (such as anti-inflammatory 
steroids, erythropoietin, progesterone) (11).
Despite promising results in preclinical settings, these 
pharmacological neuroprotective compounds have proved 
disappointing in human studies. In the last three decades, more 
than 20 neuroprotective agents have been tested in clinical trials 
(11) without proof of significant outcome improvement. A recent 
overview of more than 10 “robust” studies (multicenter, including 
more than 100 patients, with an appropriate design and a low risk 
of bias) enrolling more than 15,000 patients confirms their failure 
to demonstrate any positive result (12).
This translational failure may have numerous reasons, both in 
the clinical and in the preclinical settings.
Subsequent reappraisals concerning the study design and 
conduction of clinical trials have been published (11, 13, 14). 
These analyses identified a number of possible critical factors 
that may have counteracted the neuroprotective potential of the 
compounds, for instance:
 – the extent of side effects of the drugs and the occurrence of 
serious systemic complications
 – the small sample size with inadequate statistical power
 – the enrollment of patients too severe or too mild to detect any 
benefit
 – the use of outcome scales insensitive to important conse-
quence of brain injury
 – the high heterogeneity of TBI population without the use of 
statistical tools for important covariate adjustment
 – the inter-center variability in clinical care and clinical outcome.
To overcome this long list of limitations inherent to randomized 
clinical trials an alternative approach, devoted to Comparative 
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Effectiveness Research, is currently ongoing. An example is the 
Collaborative European NeuroTrauma Effectiveness Research in 
TBI (CENTER-TBI1), a large scale international project aiming 
at collection of demographic, clinical, imaging, genetic, and pro-
teomic data from 5,400 TBI patients (15). The main objectives are 
to improve TBI characterization and classification and to identify 
the best clinical care, using comparative effectiveness research 
approach. CENTER-TBI and other similar projects running in 
Europe and North America, coordinated in the International 
Initiative for Traumatic Brain Injury Research (InTBIR2) are 
expected to provide high quality data, and rigorous statistical 
analysis, for improving care and outcome in TBI.
There is also the possibility that the preclinical findings 
were weaker than expected. First, there are limitations in the 
experimental models used, which exploit a single traumatic 
mechanism, such as direct impact or blast waves. However, no 
single mechanism can reproduce the wide pathophysiological and 
epidemiological heterogeneity of TBI—a very complex disorder. 
This means that a therapeutic effect detected in a homogeneous 
animal population exposed to a single type of injury may well 
not be generalizable to the human TBI population. Second, the 
quality of some experimental studies is variable (16, 17), and 
there is the risk of stressing positive results. It is recognized that 
blind assessment of the effect, animal randomization, and other 
indicators of quality are inversely related to the effect size in 
several published studies on brain injury (18). Third, the papers 
with negative results are less likely to be accepted for publication. 
This bias skews the literature and makes any thorough evaluation 
of treatment effects difficult or impossible (16–18).
In recent years, new approaches and research strategies have 
been proposed (19–21) to overcome these obstacles (see Panel). 
Operation Brain Trauma Therapy (21) moves in this direction. 
OBTT is a consortium of established preclinical TBI investigators 
supported by the US Army. It aims at identifying promising acute 
therapies for TBI, testing their efficacy across different animal mod-
els and laboratories through rigorous neurological examinations, 
motor and cognitive tests, brain and lesion volume measures, and 
biomarkers (22). OBTT recently reported that the neuroprotective 
effect of four (out of five) potential treatments, rigorously re-tested, 
was weaker than previously indicated in the literature (22). Those 
negative findings highlight the need for improving research stand-
ards in both preclinical and clinical research.
neUROPROTeCTiOn AT THe BeDSiDe
Repeated failures of pharmacological neuroprotective trials have 
blunted the enthusiasm for potential new wonder drugs. The 
number of industry-sponsored studies has markedly dropped, 
with eight new trials started in 1995–1999 but only one from 
2005 to 2009 (13). Interestingly, failures occurred in the decades 
(1980–2010) during which the fundaments of neurocritical care 
1 https://www.center-tbi.eu.
2 https://intbir.nih.gov/.
were established and specialized care for severe brain injury 
emerged as a discipline.
The first textbook on “Neurological and Neurosurgical 
Intensive Care” was published by Alan Ropper and Sean Kennedy 
in 1983 (23). In 1995, the Society of Critical Care Medicine estab-
lished a neuroscience section; in 2002, the NeuroCritical Care 
Society was founded. Growing interest in acute brain injury led 
to a pragmatic approach toward neuroprotection. While awaiting 
revolutionary pharmacological interventions, it became evident 
that additional, second insults after initial injury were frequent, 
and could be prevented and/or minimized in clinical practice. 
The hypothesis was that clear identification and correction of 
aggravating factors such as arterial hypotension could reduce the 
total burden imposed by TBI on the central nervous system and 
could consequently improve outcomes.
In this section, we describe some aspects of current ICU prac-
tice as part of a comprehensive strategy for minimizing insults to 
the injured brain and restoring brain homeostasis.
early Phases after Brain Trauma: Hypoxia 
and Hypotension
Hypoxia (defined as arterial oxygen tension less than 60 mmHg or 
peripheral saturation of oxygen less than 90%) and hypotension 
(defined as systolic arterial blood pressure less than 90 mmHg) 
(24) in the early phases after TBI are frequent and dangerous 
insults (24–26). They are fundamental predictors of bad outcome 
(27, 28). Hypoxia may have multiple causes: direct traumatic 
pulmonary damage (contusion, pneumothorax, hemothorax), 
altered gas exchange (shunt, leakage because of increased capil-
lary permeability), and lack of airway protection due to impaired 
consciousness. Hypotension is most frequently caused by massive 
hemorrhage or cardiac tamponade.
Hypoxia and hypotension may worsen outcomes through two 
fundamental mechanisms: they may be associated with severe 
extracranial lesions, such as irreversible shock, which on its own 
can worsen mortality. Then too, they may amplify the initial 
damage by impairing oxygen and glucose delivery to an already 
compromised brain (Figure 1).
Correction of hypoxia and hypotension with prompt airway 
management, support ventilation, and fluid resuscitation is man-
dated by international guidelines (29, 30). Airway protection with 
tracheal intubation, which has been debated in the past (31), is rec-
ommended in all patients suffering severe TBI (32). Hypotension 
must always be avoided and corrected with isotonic fluids and, 
when necessary, vasopressors. The long-standing debate on hyper-
tonic fluid is still ongoing, with no evidence of superiority. On the 
other hand, albumin should be avoided. A recent re-analysis of the 
SAFE data (33) in the subgroup of TBI patients showed albumin 
infusion was directly related to higher intracranial pressure (ICP) 
and worse outcome (34). Blood components should be supplied, to 
optimize oxygen delivery with an adequate hemoglobin level and 
restore coagulation in hemorrhagic patients (35).
While no study has quantified the protective effect of careful 
avoidance of hypoxia and hypotension, the extent of additional 
damage they cause has been well documented in experimental 
conditions (36–38). A schematic revision of Traumatic Coma 
FiGURe 1 | Continued
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FiGURe 1 | Continued  
Dealing with potential brain insults at the bedside. Preservation of brain homeostasis requires careful detection of multiple threats, listed on the left side of the figure. 
Reduced delivery of metabolic substrate and/or increased cerebral metabolic rate of oxygen (CMRO2) are the common pathophysiological mechanisms that may 
alter brain homeostasis. The key elements in oxygen delivery are blood oxygen content and cerebral blood flow (CBF). The first may be limited by hypoxia 
(secondary to respiratory failure) or by low hemoglobin. Continuous monitoring of CBF in the ICU is difficult but it can be estimated from cerebral perfusion pressure 
(CPP). Arterial hypotension and/or elevated intracranial pressure (ICP) [secondary to increased cerebral blood volume (CBV), hematomas, contusion, hydrocephalus, 
and edema] can reduce CBF. Cerebral vasoconstriction secondary to hypocapnia and spreading depolarization can also limit CBF. Glucose delivery is guaranteed 
by CBF and blood glucose levels. Factors limiting CBF and hypoglycemia (common during intensive insulin therapy) can reduce its supply. Seizures and fever are 
common causes of high CMRO2 in the acute phase of traumatic brain injury. By leading to cerebral vasodilatation, they can raise CBV and ICP, lower CPP, and limit 
CBF and substrate delivery. Unfortunately, preserving the delivery of oxygen and glucose may not be enough to maintain cerebral homeostasis if their utilization is 
impaired by mitochondrial dysfunction.
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Data Bank findings on 717 patients indicated mortality around 
25%, in the absence of hypoxia and hypotension; this increased 
threefold for patients suffering hypoxia and hypotension (24). 
It seems likely, therefore, that preserving the injured brain from 
additional hypoxic–hypotensive insults could be beneficial.
iCP—Cerebral Perfusion Pressure (CPP)
A large amount of observational data (39–42) confirms the 
association between high ICP and unfavorable outcome, and 
particularly with increased mortality. High ICP may directly 
cause brainstem compression and distortion, which explains its 
relationship with mortality (43). It may also cause a critical reduc-
tion of CPP, leading to brain ischemia (Figure 1).
A recent South-American trial (44) on severe TBI, using a treat-
ment strategy based on ICP monitoring compared with a clinical 
and CT-based strategy, failed to show better outcomes in the ICP 
group; nevertheless, the value of ICP monitoring still stands (45). 
Recent guidelines (46) have incorporated this trial, but still suggest 
ICP monitoring for reducing early mortality after TBI.
Cerebral perfusion pressure, calculated as mean arterial pres-
sure minus ICP, is vital to perfuse the brain because it is the driv-
ing force for cerebral blood flow (CBF). The accepted threshold is 
commonly set at 60 mmHg (46, 47) but a higher threshold might 
be warranted in patients with impaired autoregulation due to 
chronic arterial hypertension (48).
The first strategy against dangerous ICP increases and CPP reduc-
tions is prompt recognition and removal of expanding intracranial 
hematomas (43). Reports based on few cases are extremely eloquent 
and prove that removal of subdural hematomas, while initially caus-
ing a destructive reduction of CPP and CBF (49) allowed restoration 
of cerebral perfusion (50). In this perspective, emergency surgery is 
an indisputable, effective neuroprotective strategy.
The treatment of increased ICP is based on a graded approach 
(43), with basic treatment (including sedation and supported 
ventilation) for all patients; more invasive therapy has to be 
reserved for more severe cases. Extreme therapies are only 
recommended for refractory intracranial hypertension, because 
of troublesome side effects. The concept of dosing therapy and 
applying more aggressive interventions only to selected patients 
is also evident from recent trials (51, 52). When highly invasive 
treatments, such as hypothermia or surgical decompression, were 
applied to patients with relatively low ICP, the outcome was worse 
in the treated group.
In clinical practice, careful ICP and CPP monitoring, coupled 
with tailored therapies, are fundamental neuroprotective tools: 
a first-line defense against brain stem compression and critical 
CBF reductions.
Advanced intracranial Monitoring: PbtO2 
and Microdialysis
Inadequate substrate delivery (mainly oxygen and glucose) to 
the brain is an obvious cause of tissue hypoxia, metabolic distur-
bances, and potential metabolic crisis. Multimodal monitoring 
(53) offers the possibility of measuring (and possibly optimizing) 
several key metabolic parameters in limited volumes of the brain.
Partial brain tension of oxygen (PbtO2) can be continuously 
measured with specific probes, and microdialysis can be used to 
sample the extracellular concentrations of glucose, lactate, and pyru-
vate at specified intervals, usually hourly (53, 54). Besides CPP, which 
may give indirect information on the global CBF driving pressure, 
these parameters may capture signs of hypoxia, hypoperfusion, and 
downstream metabolism disturbances. Reduction of PbtO2 below a 
threshold of 20–25 mmHg is associated with worse outcome (55–57).
Microdialysis offers an insight on the metabolic profile of the 
brain; a normal lactate/pyruvate ratio (LPR) (usually lower than 
25) indicates physiologic glucose utilization through the Krebs 
cycle. The LPR reflects the redox state of the brain (54). When 
measured together with the extracellular glucose concentration, 
and possibly with PbtO2, different metabolic profiles can be identi-
fied. For instance, a low glucose concentration coupled with a high 
LPR and low PbtO2 is consistent with ischemia; mitochondrial 
dysfunction is suspected when a normal glucose concentration 
and normal PbtO2 are found simultaneously with a high LPR (58). 
Metabolic disturbances measured by microdialysis are linked with 
worse outcome after TBI (53, 59). Early or persistent oxidative 
metabolic dysfunction has been correlated with brain atrophy (60).
These advanced monitoring techniques may measure the ade-
quacy of oxygen and substrate delivery to the brain and identify 
dangerous alterations. Additional information besides traditional 
surveillance (based only on ICP and CPP), as provided by PbtO2, 
has given encouraging results (61). Therefore, advanced multi-
modal monitoring could improve insult detection at the bedside 
and contribute to better brain protection.
Brain electrical Disturbances during the 
iCU Course after TBi
Traumatic brain lesions, particularly after penetrating injury, 
are a major risk factor for seizures (62). Guidelines recommend 
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early prophylaxis with phenytoin to prevent seizures in the first 
week after TBI (46). TBI patients are exposed to other electrical 
disturbances as well, such as non-convulsive status epilepticus 
(NCSE) and spreading depolarization. NCSE has been diagnosed 
with variable incidence in TBI series (63, 64), often regardless of 
the use of antiepileptic drugs.
Pathological waves of sustained depolarization that propagate 
through the cerebral gray matter are attracting increasing research 
interest. They are indicated as spreading depolarization (65) and 
are associated with microvascular and metabolic alterations. 
Their exact pathological role and the potential benefit of specific 
treatments are still under investigation.
Seizures and analogous electrical disturbances (65, 66) demand 
energy. Uncontrolled hyperactivity of neurons can induce or 
worsen a metabolic crisis in the injured brain. Therefore, preven-
tion of seizures and appropriate monitoring of electric activity (in 
selected cases by continuous EEG) can help prevent, or disclose, 
noteworthy second insults (67), offering additional protection.
Fever
Hyperthermia is deleterious to the damaged brain (68, 69). It can 
exacerbate ischemic injury (by increasing the brain’s metabolic 
demand) and may cause vasodilation of the cerebral vessels. This 
increases the brain–blood volume and may worsen ICP (70). 
Ample evidence indicates that fever is dangerous in TBI patients, 
worsening morbidity, and mortality (71).
While repeated trials have reported that hypothermia offers no 
benefit (51, 72), it is agreed that hyperthermia is definitely an insult 
after TBI. Careful temperature monitoring, and treatment of fever, 
may therefore reduce further brain damage in the acute phase.
COnCLUSiOn
The paradox of neuroprotection in TBI is that, despite a long list 
of potential neuroprotective agents active under experimental 
conditions, no compound has demonstrated protection in clini-
cal trials. Analysis of clinical and preclinical trials has identified 
several gaps and improvements are certainly needed. However, 
even the most rigorous scrutiny of evidence and the highest 
research standard, as proposed by OBTT, do not guarantee suc-
cess: a similar initiative in ischemic stroke (73) led to a negative 
clinical trial (74).
While awaiting an effective molecule limiting secondary brain 
injury after trauma, good-quality neurointensive care can provide 
modest but effective neuroprotection. By monitoring systemic 
and neurological parameters, intracranial and extracranial 
threats can be identified. In this way, effective targeted therapies 
become possible, and the burden of additional insults to the brain 
might be lightened.
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